Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis, counteract negative nitrogen balance, and maintain muscle mass. Dextrose supplies calories for energy metabolism, and electrolytes correct or prevent imbalances.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
1-2 L/day intravenously, infused at a rate of 1-2 mL/kg/hour (50-100 mL/hour) for a 70 kg adult, adjusted based on nitrogen and caloric needs.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours depending on metabolic demand and renal function. Dextrose has a half-life of 15-20 minutes under normal conditions. In renal impairment, half-life of amino acid byproducts may prolong.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Urea (from amino acid metabolism) is excreted renally. Electrolytes and dextrose metabolites are eliminated via renal and respiratory routes. No significant biliary/fecal elimination.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution